Concizumab promotes haemostasis via a tissue factor-factor VIIa-dependent mechanism supporting prophylactic treatment of haemophilia: Results from a rabbit haemophilia bleeding model

Haemophilia. 2019 Nov;25(6):e379-e382. doi: 10.1111/hae.13861. Epub 2019 Oct 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Disease Models, Animal
  • Factor VIIa / metabolism
  • Female
  • Hemophilia A / blood
  • Hemophilia A / complications
  • Hemophilia A / drug therapy*
  • Hemophilia A / metabolism
  • Hemorrhage / blood
  • Hemorrhage / complications
  • Hemorrhage / drug therapy*
  • Hemorrhage / metabolism
  • Hemostasis / drug effects*
  • Rabbits
  • Thromboplastin / metabolism

Substances

  • Antibodies, Monoclonal, Humanized
  • concizumab
  • Thromboplastin
  • Factor VIIa

Grants and funding